Psyence Biomedical (PBM) FDA Approvals $2.75 -0.16 (-5.50%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.89 +0.14 (+5.24%) As of 06/24/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Psyence Biomedical's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Psyence Biomedical (PBM). Over the past two years, Psyence Biomedical has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as NPX-5. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. NPX-5 FDA Regulatory Events NPX-5 is a drug developed by Psyence Biomedical for the following indication: for Adjustment Disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Dosing Update - April 23,2026Dosing Update Phase 2bDrug: NPX-5Announced Date: April 23, 2026Indication: for Adjustment DisorderAnnouncementPsyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.AI SummaryPsyence Biomedical Ltd. announced the first patient has been dosed in its Phase IIb clinical trial of NPX-5 (25 mg nature-derived psilocybin) for Adjustment Disorder in patients with cancer receiving palliative care. This marks the company’s first large-scale human evaluation of NPX-5 and the start of systematic data generation across five Australian clinical sites, including centers in Perth and Melbourne. NPX-5 is described as a GMP-compliant, nature-derived psilocybin developed through PsyLabs as part of Psyence’s vertically integrated platform. The randomized, double-blind, three-arm trial will assess safety, tolerability, clinical response, and treatment durability when psilocybin is given alongside structured therapeutic support. The study’s results are intended to inform future development and potential regulatory pathways. Dr. Neil Maresky said the team is focused on disciplined execution, consistent patient recruitment, and producing high-quality data to evaluate the therapeutic potential of a 25 mg dose.Read Announcement Psyence Biomedical FDA Events - Frequently Asked Questions Has Psyence Biomedical received FDA approval? As of now, Psyence Biomedical (PBM) has not received any FDA approvals for its therapy in the last two years. What drugs has Psyence Biomedical submitted to the FDA? In the past two years, Psyence Biomedical (PBM) has reported FDA regulatory activity for NPX-5. What is the most recent FDA event for Psyence Biomedical? The most recent FDA-related event for Psyence Biomedical occurred on April 23, 2026, involving NPX-5. The update was categorized as "Dosing Update," with the company reporting: "Psyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting." What conditions do Psyence Biomedical's current drugs treat? Currently, Psyence Biomedical has one therapy (NPX-5) targeting the following condition: for Adjustment Disorder. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Cybin FDA EventsREGENXBIO FDA EventsViking Therapeutics FDA EventsWAVE Life Sciences FDA EventsMerck & Co., Inc. FDA EventsAgomAb Therapeutics FDA EventsAmylyx Pharmaceuticals FDA EventsCoherus Oncology FDA EventsDiaMedica Therapeutics FDA EventsEntera Bio FDA EventsGalectin Therapeutics FDA EventsGilead Sciences FDA EventsJaguar Animal Health FDA EventsKalaris Therapeutics FDA EventsMicrobot Medical FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Jasper Therapeutics FDA Events Akari Therapeutics FDA Events Phio Pharmaceuticals FDA Events LianBio FDA Events Chemomab Therapeutics FDA Events Kiora Pharmaceuticals FDA Events BioCardia FDA Events Brainstorm Cell Therapeutics FDA Events Aprea Therapeutics FDA Events Traws Pharma FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:PBM last updated on 4/23/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dosing Update - April 23,2026Dosing Update Phase 2bDrug: NPX-5Announced Date: April 23, 2026Indication: for Adjustment DisorderAnnouncementPsyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.AI SummaryPsyence Biomedical Ltd. announced the first patient has been dosed in its Phase IIb clinical trial of NPX-5 (25 mg nature-derived psilocybin) for Adjustment Disorder in patients with cancer receiving palliative care. This marks the company’s first large-scale human evaluation of NPX-5 and the start of systematic data generation across five Australian clinical sites, including centers in Perth and Melbourne. NPX-5 is described as a GMP-compliant, nature-derived psilocybin developed through PsyLabs as part of Psyence’s vertically integrated platform. The randomized, double-blind, three-arm trial will assess safety, tolerability, clinical response, and treatment durability when psilocybin is given alongside structured therapeutic support. The study’s results are intended to inform future development and potential regulatory pathways. Dr. Neil Maresky said the team is focused on disciplined execution, consistent patient recruitment, and producing high-quality data to evaluate the therapeutic potential of a 25 mg dose.Read Announcement
